BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Capivasertib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Capivasertib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03903835-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capivasertib: Phase 3 readout est. (NCT03903835)
DESCRIPTION:Capivasertib\, phase 3\, Prostate Cancer.\nStudy: ProBio: A Bio
 marker Driven Study in Patients With Metastatic Prostate Cancer\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/capivasertib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03903835
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05563220-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Capivasertib: Phase 1/2 readout est. (NCT05563220)
DESCRIPTION:Capivasertib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elace
 strant In Various Combination In Participants With Metastatic Breast Cance
 r\nEstimated primary completion: 27 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/capivasertib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05563220
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03772561-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capivasertib: Phase 1 readout est. (NCT03772561)
DESCRIPTION:Capivasertib\, phase 1.\nStudy: Phase I Study of AZD5363 + Olap
 arib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Mali
 gnancies\nEstimated primary completion: 31 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/capivasertib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03772561
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07426822-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Capivasertib: Phase 2 readout est. (NCT07426822)
DESCRIPTION:Capivasertib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Rash & Diarrhea Prophylaxis With Capivasertib\nEstimated primary com
 pletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 capivasertib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07426822
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04812366-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Capivasertib: Phase 2 readout est. (NCT04812366)
DESCRIPTION:Capivasertib\, phase 2\, Prostate Cancer.\nStudy: Genomic Bioma
 rker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate 
 Cancer\nEstimated primary completion: 1 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/capivasertib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04812366
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862663-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Capivasertib: Phase 3 readout est. (NCT04862663)
DESCRIPTION:Capivasertib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER
 2- Breast Cancer (CAPItello-292)\nEstimated primary completion: 1 November
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/capivasertib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04862
 663
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764186-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Capivasertib: Phase 3 readout est. (NCT06764186)
DESCRIPTION:Capivasertib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Phase IIIB Study to Evaluate the Use of Capivasertib in Combinatio
 n With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relaps
 ed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Pr
 actice in Spain\nEstimated primary completion: 30 November 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/capivasertib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06764186
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capivasertib: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Capivasertib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Targeted Therapy Directed by Genetic Testing in Treating Patients Wi
 th Advanced Refractory Solid Tumors\, Lymphomas\, or Multiple Myeloma (The
  MATCH Screening Trial)\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/capivasertib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287917-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Capivasertib: Phase 1/2 readout est. (NCT07287917)
DESCRIPTION:Capivasertib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: Study of AMXT 1501 and DFMO in Combination With Standard Therapies
  in Advanced Solid Tumors\nEstimated primary completion: 28 February 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/capivasertib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07287917
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05039801-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Capivasertib: Phase 1 readout est. (NCT05039801)
DESCRIPTION:Capivasertib\, phase 1.\nStudy: IACS-6274 With or Without Bevac
 izumab and Paclitaxel for the Treatment of Advanced Solid Tumors\nEstimate
 d primary completion: 30 March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/capivasertib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05039801
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02523014-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Capivasertib: Phase 2 readout est. (NCT02523014)
DESCRIPTION:Capivasertib\, phase 2.\nStudy: Vismodegib\, FAK Inhibitor GSK2
 256098\, Capivasertib\, and Abemaciclib in Treating Patients With Progress
 ive Meningiomas\nEstimated primary completion: 1 June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/capivasertib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT02523014
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02208375-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Capivasertib: Phase 1 readout est. (NCT02208375)
DESCRIPTION:Capivasertib\, phase 1\, Breast Cancer.\nStudy: mTORC1/2 Inhibi
 tor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial an
 d Ovarian\nEstimated primary completion: 30 June 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/capivasertib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT02208375
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05593497-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Capivasertib: Phase 2 readout est. (NCT05593497)
DESCRIPTION:Capivasertib\, phase 2\, Prostate Cancer.\nStudy: A Single-Arm 
 Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide
  and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib
 ) for High-Risk Localized Prostate Cancer With PTEN Loss\nEstimated primar
 y completion: 31 October 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/capivasertib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05593497
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486648-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Capivasertib: Phase 1/2 readout est. (NCT07486648)
DESCRIPTION:Capivasertib\, phase 1/2.\nStudy: Osimertinib Plus Capivasertib
  in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib
 \nEstimated primary completion: 15 May 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/capivasertib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07486648
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07793578-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Capivasertib: Phase 1/2 readout est. (NCT07793578)
DESCRIPTION:Capivasertib\, phase 1/2.\nStudy: Immunotherapy Plus Capivasert
 ib for Metastatic Bladder Cancer\nEstimated primary completion: 30 Septemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/capivasertib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 93578
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281833-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Capivasertib: Phase 3 readout est. (NCT07281833)
DESCRIPTION:Capivasertib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Phase III Study to Evaluate the Safety\, Efficacy\, and Impact on Qu
 ality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatme
 nt in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Pr
 ior Endocrine-based Treatment\nEstimated primary completion: March 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/capivasertib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07281833
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02813135-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Capivasertib: Phase 1/2 readout est. (NCT02813135)
DESCRIPTION:Capivasertib\, phase 1/2.\nStudy: European Proof-of-Concept The
 rapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refrac
 tory Tumors\nEstimated primary completion: February 2031. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/capivasertib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT02813135
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175415-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20311001
DTEND;VALUE=DATE:20311002
SUMMARY:Capivasertib: Phase 1/2 readout est. (NCT07175415)
DESCRIPTION:Capivasertib\, phase 1/2.\nStudy: HEM-iSMART E: Capivasertib + 
 Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refracto
 ry Hematological Malignancies\nEstimated primary completion: 1 October 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/capivasertib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07175415
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294677-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Capivasertib: Phase 1/2 readout est. (NCT07294677)
DESCRIPTION:Capivasertib\, phase 1/2.\nStudy: CApivasertib\, Venetoclax And
  Low-intensity chemotheRapY for Adults With ALL/LBL\nEstimated primary com
 pletion: March 2032. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 capivasertib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07294677
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07802626-7646@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20341030
DTEND;VALUE=DATE:20341031
SUMMARY:Capivasertib: Phase 3 readout est. (NCT07802626)
DESCRIPTION:Capivasertib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Adding Capivasertib to Standard Treatment in HR Positive\, HER2 Nega
 tive Metastatic Breast Cancer Based on ctDNA Testing\nEstimated primary co
 mpletion: 30 October 2034. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/capivasertib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07802626
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
